Since October 2020 – when the Health Sciences Authority first authorised the sale of an esketamine nasal spray ... is now a mainstream prescription for treatment-resistant depression, often ...

The hallucinogenic drug is an option when traditional treatment isn’t working ... is we can stop that antidepressant and initiate the esketamine, the Spravato, without continuing another ...

Since October 2020 – when the Health Sciences Authority (HSA) first authorized sale of an esketamine nasal spray ... is available at about 2,800 treatment centers worldwide as at late 2024 ...

For treatment-resistant depression, patients usually get the esketamine nasal spray twice ... The doctor isn’t necessarily in the room with the person being treated but is available if they ...

Q4 earnings for companies such as Johnson & Johnson, Teva, and Roche highlight the impact of significant innovations brought ...

MGM Grand Announces $300 Million Room and Suite ... SPRAVATO ® (esketamine) approved in the U.S. as the first and only monotherapy for adults with treatment-resistant depression SPRAVATO ...

A ketamine-derived nasal spray is now available for the millions of Americans living with severe depression. The hallucinogenic drug is an option when traditional treatment isn’t working, but it’s not ...

Morningstar brands and products Company Portfolio ...

Esketamine, the ketamine-derived nasal spray sold under the brand name Spravato (esketamine), is indicated for patients with treatment-resistant ... They'd bring me into a room, sit me down ...

2 Owing to the strong discomfort associated with endoscopic treatment and the proposal to provide comfortable ... to a specific nurse who will prepare the study medicine in a closed room until the end ...

The following is a summary of “Esketamine Treatment for Depression in Adults: A PRISMA Systematic Review and Meta-Analysis,” published in the January 2025 issue of Psychiatry by Fountoulakis et al.